| Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
Risk factor | OR (95% CI) | p-value | OR (95% CI) | p-value |
Male gender (vs. Female) | 3.38 (0.41-27.32) | 0.25 | Â | Â |
Age ≥70 years (vs. ≤69 years) | 0.67 (0.17-2.53) | 0.55 |  |  |
Tumor location Lower (vs. Upper and Middle) | 1.05 (0.28-3.99) | 0.55 | Â | Â |
Continued use of LDA | 1.98 (0.23-16.4) | 0.52 | Â | Â |
Continued use of LDA + heparin replacement | N/A | N/A |  |  |
Heparin replacement | 13.89 (3.48-55.39) |  <0.01* | 12.23 (2.63-56.77) |  <0.01* |
Cessation of antithrombotic agent during ESD procedure (vs. No antithrombotic therapy) | N/A | N/A | Â | Â |
Liver cirrhosis | 1.67 (0.20-13.9) | 0.63 | Â | Â |
CKD undergoing hemodialysis | 33.16 (6.67-164.82) |  <0.01* | 28.35 (4.67-172.11) |  <0.01* |
Specimen size ≥40 mm (vs. < 40 mm) | 0.92 (0.19-4.55) | 0.92 |  |  |
Procedure time ≥90 min (vs. < 90 min) | 2.56 (0.67-9.78) | 0.16 |  |  |
Second-look endoscopy (vs. No second-look endoscopy) | N/A | N/A | Â | Â |